Drugs / Equecabtagene Autoleucel
Equecabtagene Autoleucel
Trials 4 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT05698303 | May 2023 → May 2024 | plasma cell myeloma | Nanjing IASO Biotechnology Co., Ltd. | Unknown | No outcome recorded |
| Phase 21 trial | ||||||
| Phase 2 | NCT07055724 | Jul 2025 → Jun 2027 expected | AL amyloidosis | Nanjing IASO Biotechnology Co., Ltd. | Not yet recruiting | No outcome recorded |
| Phase 31 trial | ||||||
| Phase 3 | NCT06464991 | Mar 2024 → Aug 2027 expected | plasma cell myeloma | Nanjing IASO Biotechnology Co., Ltd. | Recruiting | No outcome recorded |
| Phase not applicable1 trial | ||||||
| — | NCT06902844 | Apr 2025 → Oct 2027 expected | lupus nephritis, systemic lupus erythematosus | Tongji Hospital | Recruiting | No outcome recorded |
Evidence & citations 5 cited values
Every value below carries the sentence it was read from. 5 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Equecabtagene Autoleucel | “Equecabtagene autoleucel (Fucaso®), an autologous anti-B cell maturation antigen (BCMA)-directed chimeric antigen receptor (CAR)-T cell therapy” PMID 37658205 ↗ Sep 2023 |
| Known as | Eque-cel | “This is a single-center, open-label, exploratory clinical study to evaluate the efficacy and safety of Equecabtagene Autoleucel Injection (Eque-cel) in patients with Relapsed...” NCT06902844 ↗2“Equecabtagene Autoleucel (eque-cel) is an autologous chimeric antigen receptor T-cell (CAR-T) therapy” NCT06464991 ↗ “Equecabtagene Autoleucel, Eque-cel” NCT07055724 ↗ |
| Known as | Fucaso | “Equecabtagene autoleucel (Fucaso®), an autologous anti-B cell maturation antigen (BCMA)-directed chimeric antigen receptor (CAR)-T cell therapy” PMID 37658205 ↗ Sep 2023 |
| Action | Deplete | “identifies and eliminates BCMA-expressing malignant and normal cells” NCT05698303 ↗ |
| Modality | Cell therapy | “autologous anti-B cell maturation antigen (BCMA)-directed chimeric antigen receptor (CAR)-T cell therapy” PMID 37658205 ↗ Sep 2023 |